RB’s OTC business rises by a third amid COVID-19

8 May 2020 - Deborah Wilkes

Premium

Worldwide sales at RB’s OTC business shot up by a third on a like-for-like basis in the first quarter of 2020 as demand was boosted by the COVID-19 pandemic. RB said there had been “exceptional demand” for Mucinex in North America and for Nurofen in Europe, Australia and New Zealand.

Click tags below for more information on topics:

RB COVID-19

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: